[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monkeypox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monkeypox":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,78,105,133,158,183,206,231,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100482460","characterization-of-vaccine-induced-responses-against-monkeypox-movihvax-an-observational-prospective-cohort-study-100482460",false,"NCT05562323","Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study","Inclusion Criteria:\n\n1. Adult individuals of ≥18 years old.\n2. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the trial.\n3. Has understood the information provided and capable of giving informed consent.\n\nExclusion Criteria:\n\n1\\. Participant has any medical condition and\u002For finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This observational study has been designed to characterize humoral and cellular immune responses after vaccination against monkeypox (MKP) in HIV positive and negative individuals at high risk of MKP infection during the vaccination campaign in the current monkeypox outbreak.",[23],"Monkeypox",[25,26,27],"Monkeypox vaccine","Immune responses","HIV","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"2022-09-14",{"date":36,"type":19},"2026-08",{"name":38,"class":39},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","OTHER",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":20,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100634021","understanding-mpxv-viral-clearance-transmission-dynamics-and-mpox-vaccine-effectiveness-in-west-africa--guinea-100634021","NCT07534267","Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea","Understanding MPXV Viral Clearance in Mpox Patients and Evaluating Transmission Dynamics of MPXV and Mpox Vaccine Effectiveness in West Africa : The Republic of Guinea","MOVIE-TRACE-WA","Inclusion Criteria:\n\n1. MOVIE-West Africa\n\n   * Individuals of any sex and age.\n   * Confirmed Mpox cases who tested positive for MPXV by PCR.\n   * Symptom onset within the 10 days prior to the baseline assessment.\n   * Willingness and ability to comply with study procedures and attend scheduled follow-up visits for up to two months.\n   * Availability for follow-up throughout the study period.\n   * Provision of written informed consent by the participant, or consent by a legally authorized representative for minors or individuals unable to provide it themselves.\n   * Assent obtained from children aged 12 to 17 years.\n   * For individuals who cannot read or write, witnessed consent will be obtained.\n2. TRACE-West Africa\n\n   * Individuals who have had close physical contact with a PCR-confirmed Mpox case within 14 days from the onset of symptoms in the index case.\n   * Close physical contact is defined as being within 2 meters of an infected person-particularly in enclosed spaces-for at least 5 minutes (based on CDC's 2-meter rule for droplet transmission).\n   * Willingness and ability to comply with the study protocol and attend scheduled follow-up assessments.\n   * Provision of written informed consent by the participant, or consent by a legally authorized representative for individuals unable to provide it themselves.\n   * Assent obtained from children aged 12 to 17 years.\n   * For individuals who cannot read or write, witnessed consent will be obtained.\n3. VE-West Africa\n\n   * The inclusion criteria for Mpox cases in VE-West Africa are same as those in MOVIE-West Africa.\n   * The inclusion criteria for contacts of Mpox cases in VE-West Africa are as follows.\n   * Individuals who have had close physical contact with a PCR-confirmed Mpox case within 14 days from the onset of symptoms in the index case.\n   * Close physical contact is defined as being within 2 meters of an infected person-particularly in enclosed spaces-for at least 5 minutes (based on CDC's 2-meter rule for droplet transmission).\n   * Individuals living, working or studying in a community where mpox vaccination is being offered.\n   * Willingness and ability to comply with the study protocol and attend scheduled follow-up assessments.\n   * Provision of written informed consent by the participant, or consent by a legally authorized representative for individuals unable to provide it themselves.\n   * Assent obtained from children aged 12 to 17 years.\n   * For individuals who cannot read or write, witnessed consent will be obtained.\n\nExclusion Criteria:\n\n(1) MOVIE-West Africa\n\n* Cases of severe Mpox requiring hospitalization.\n* Individuals with a confirmed alternative diagnosis explaining their illness.\n\n  (3) VE-West Africa\n* The exclusion criteria for Mpox cases in VE-West Africa are as follows.\n* Cases of severe Mpox requiring hospitalization.\n* Individuals with a confirmed alternative diagnosis explaining their illness.",true,{"count":51,"type":19},992,"56 Days","This study has three primary objectives to address the public health challenges of the Mpox outbreak in Guinea, West Africa. Objective 1 (MOVIE-West Africa) focuses on understanding the kinetics of Monkeypox virus (MPXV) elimination from the human body in Mpox cases. Objective 2 (TRACE-West Africa) aims to determine the MPXV transmission dynamics between Mpox cases and their contacts. Objective 3 (VE-West Africa) examines the vaccine effectiveness of the MVA-BN vaccine in protection against MPXV infection and Mpox disease.",[55,23],"Mpox (Monkeypox)",[57,23,58,59,60,61,62,63,64,65,66,67],"Mpox","MPXV","transmission dynamics","vaccine effectiveness","secondary attack rate","MVA-BN","Guinea","sub-Saharan Africa","West Africa","MOVIE-TRACE","viral clearance","NOT_YET_RECRUITING","2026-04-10",{"date":71,"type":32},"2026-04-16",{"date":71,"type":19},{"date":74,"type":19},"2027-08",{"name":76,"class":39},"London School of Hygiene and Tropical Medicine",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":77},"100506867","prospective-study-for-the-follow-up-of-human-monkeypox-cases-and-smallpox-vaccinees-at-risk-100506867","NCT05879965","Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","Prospective On-site and Questionnaire Study for the FOLLOW-UP of Mpox Cohort at ITM PLUS Evaluation of the Longevity of B- and T-cell Immune Responses in Former Mpox Patients and Vaccine Recipients","POQS-FU PLUS","Mpox patients for immunological study\n\nInclusion criteria\n\n* PCR-confirmed mpox infection since May 2022\n* ≥18 years\n* Willingness to provide written informed consent\n* Willingness to follow the study schedule\n\nExclusion criteria\n\n* Any vaccination 2 weeks before or after the visits (4 weeks for life-vaccines)\n* Any immune-compromising drugs or diseases (treated and controlled HIV-infection is no exclusion criteria)\n* Any mpox reinfection since study start\n\nSmallpox vaccinees for immunological study\n\nInclusion criteria\n\n* At least two smallpox vaccinations.\n* ≥18 years\n* Willingness to provide written informed consent\n* Willingness to follow the study schedule\n\nExclusion criteria\n\n* Any vaccination 2 weeks before or after the visits (4 weeks for life-vaccines)\n* Any immune-compromising drugs or diseases (treated and controlled HIV-infection is no exclusion criteria)\n* Any mpox infection in the past\n\nHIV-Prep patients\n\nInclusion criteria\n\n* On HIV-PrEP and a patient from ITM\n* ≥18 years\n* Willingness to provide written informed consent\n* Willingness to follow the study schedule\n\nExclusion criteria\n\n* Born before 1976\n* Any documented or remembered smallpox vaccination or typical scar for a smallpox vaccination\n* Any vaccination 2 weeks before or after the visits (4 weeks for life-vaccines)\n* Any immune-compromising drugs or diseases\n* Any mpox infection in the past",{"count":87,"type":19},345,"The goal of this observational study is to describe possible physical and psychological sequelae after an mpox infection and to evaluate the longevity of B- and T-cell immune responses in former mpox patients and vaccine recipients.\n\nThe main questions it aims to answer are:\n\n* Are there any physical or pschological sequelae after mpox infection?\n* Is the humoral and\u002For cellular immune response to MPOX (or vaccinia) virus) durable?\n* Do the patients develop strong local immunity in comparison to systemic immunity?\n* How long is the virus still detectable in semen, saliva or the ano-rectal region?\n\nParticipants will answer a questionnaire, samples with blood, saliva and semen as well as anal swabs will be collected. Follow-up visits 8, 16 and 24, 36, 48, and 60 months after infection or vaccination are planned.\n\nA healthy control group will be recruited in our HIV-PrEP clinic.",[23],[91,92,93,94,95],"mpox","immunology","mucosal immunity","sequelae","smallpox vaccination","2026-03-17",{"date":98,"type":32},"2026-03-19",{"date":100,"type":32},"2022-10-06",{"date":102,"type":19},"2028-06",{"name":104,"class":39},"Institute of Tropical Medicine, Belgium",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":77},"100621942","phase-1-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-bsy001-after-singlemultiple-doses-100621942","NCT07377175","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single\u002FMultiple Doses.","A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects.","Inclusion Criteria:\n\n1. Subjects voluntarily participate in the study, sign the informed consent form, and agree to comply with all study requirements;\n2. Aged ≥ 18 years and ≤ 50 years (based on the date of signing the informed consent form), including both males and females;\n3. Body Mass Index (BMI) between 19.0 and 30.0 kg\u002Fm² (19.0 and 30.0 kg\u002Fm² inclusive); for female subjects, body weight between 45.0 and 120.0 kg (45.0 kg inclusive and 120.0 kg exclusive); for male subjects, body weight between 50.0 and 120.0 kg (50.0 kg inclusive and 120.0 kg exclusive);\n4. Subjects (including their partners) voluntarily adopt effective contraceptive measures from 1 month before screening to 6 months after the last administration of the study drug, and have no plans for childbearing, sperm donation, or egg donation within the next 6 months.\n\nExclusion Criteria:\n\n1. Subjects with a known allergy to Tecovirimat drugs, any excipient ingredients in this product, or subjects with an allergic diathesis (allergic to ≥ 2 types of substances);\n2. Subjects with clinically significant abnormal electrocardiogram (ECG) findings or QTc prolongation as determined by the investigator (e.g., QTc interval ≥ 450 ms in males and ≥ 470 ms in females, with QTc interval calculated using the Fridericia formula);\n3. Subjects with a creatinine clearance rate (Cockcroft-Gault formula) \\\u003C 90 mL\u002Fmin;\n4. Subjects with clinically significant abnormalities in physical examination, vital signs, laboratory tests, or other auxiliary examinations as determined by the investigator;\n5. Subjects with current or past history of the following clinically significant diseases as determined by the investigator, including but not limited to diseases of the cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, immune system, and nervous system (e.g., epilepsy);\n6. Subjects with a current or history (within the past 3 months) of bacterial, fungal, or mycobacterial infection.;\n7. Subjects with known clinically significant acute\u002Fchronic viral infections;\n8. Subjects with a history of severe headache or migraine;\n9. Subjects who have undergone major surgery within 6 months before drug administration, or plan to undergo surgery from the time of signing the informed consent form to 1 month after the end of the trial;\n10. Subjects who have donated blood or had massive blood loss (\\> 450 mL) within 3 months before screening;\n11. Subjects who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form, or cannot refrain from using any tobacco products during the trial;\n12. Subjects who consumed more than 14 units of alcohol per week within 3 months before signing the informed consent form (1 unit of alcohol ≈ 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine), had a positive alcohol breath test (breath alcohol content \\> 0 mg\u002F100 mL), or cannot abstain from alcohol during the trial;\n13. Subjects who consumed grapefruit, grapefruit juice, chocolate, strong tea, coffee, or other beverages containing caffeine or alcohol within 72 hours before drug administration, or refuse to stop consuming the aforementioned beverages and foods during the trial;\n14. Subjects who plan to engage in strenuous exercise during the trial, including contact sports or collision sports;\n15. Subjects with a positive urine drug screen (for morphine, methamphetamine, ketamine, 3,4-methylenedioxymethamphetamine, or tetrahydrocannabinolic acid), or a history of drug abuse or drug use within 5 years before screening;\n16. Subjects with a positive result in any of the following tests: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (IgG), hepatitis C virus core antigen, human immunodeficiency virus (HIV) antibody, or treponema pallidum-specific antibody (TP-Ab);\n17. Subjects who participated in other drug clinical trials within 3 months before screening (calculated starting from the time of the last drug administration in the previous trial);\n18. Subjects who took any prescription drugs, over-the-counter drugs, or traditional Chinese herbal medicines within 30 days before screening;\n19. Subjects with a positive pregnancy test result;\n20. Subjects who cannot tolerate venipuncture, or have a history of hematophobia (fear of blood) or trypanophobia (fear of needles);\n21. Subjects who developed an acute illness or required concomitant medication from the screening phase to before the first drug administration;\n22. Subjects who received a vaccine within 2 weeks before screening, or plan to receive a vaccine during the trial;\n23. Subjects deemed unsuitable for participation in this trial by the investigator.","50 Years",{"count":114,"type":19},76,"INTERVENTIONAL",[117],"PHASE1","A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects",[120,121,23,122],"Smallpox","Cowpox","Poxvirus Infection","2026-01-22",{"date":125,"type":32},"2026-01-29",{"date":127,"type":32},"2025-08-28",{"date":129,"type":19},"2026-02-13",{"name":131,"class":132},"China National Biotec Group Company Limited","INDUSTRY",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":115,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":77},"100575376","phase-1-a-study-evaluating-the-safety-and-immunogenicity-of-mva-strain-monkeypox-attenuated-live-vaccine-100575376","NCT06771479","A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine for Individuals Aged 18 and Above","Inclusion Criteria:\n\n* On the day of enrollment, individuals aged 18 years or older with a history of smallpox vaccination must have been born before 1980;\n* Can provide legal proof of identity;\n* Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment;\n* Be able to participate in all planned follow-up visits and comply with all trial procedures (such as completing diary\u002Fcontact cards and being able to return for visits);\n* On the day of enrollment, the body temperature was less than 37.3 ℃ (axillary temperature);\n* Men and women of childbearing age who have no plans to have children within 6 months and agree to take effective contraceptive measures within 6 months after receiving the experimental vaccine.\n\nExclusion Criteria:\n\n* Individuals with a history of smallpox, monkeypox, or close contact with monkeypox in the past;\n* Individuals who are allergic to any ingredients of eggs, vaccines, or substances used in production processes, or have a history of other severe allergies;\n* Use immunoglobulin and\u002For any blood products within 3 months prior to administering the trial vaccine, or plan to use them during the trial period;\n* Currently using salicylate drugs or planning long-term use during the trial period;\n* Have used any experimental or unregistered products within one month prior to administering the trial vaccine, or plan to use them during the trial period;\n* Administer inactivated vaccine within 14 days before administering the experimental vaccine or attenuated live vaccine within 30 days before administering the experimental vaccine;\n* Chronic disease patients are in the acute or progressive phase of chronic disease;\n* Long term use of immunosuppressants or other immunomodulatory drugs within 6 months prior to vaccination with the experimental vaccine;\n* Having undergone chemotherapy or radiation therapy or organ and bone marrow transplantation related treatments for cancer or other diseases;\n* Diseases or medical measures that lead to immune dysfunction, such as congenital immunodeficiency, organ and bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma or malignant tumors, etc;\n* Moderate or severe acute illness\u002Finfection, or febrile illness on the day of vaccination;\n* Individuals with a history of thrombocytopenia or other coagulation disorders may be contraindicated for subcutaneous injection;\n* Suffering from serious cardiovascular disease, serious liver and kidney disease, and diabetes that cannot be controlled by drugs;\n* Previous history of mental or neurological disorders or family history;\n* Currently suffering from various infectious, suppurative, and allergic skin diseases;\n* Women of childbearing age: pregnant or lactating, or with a positive blood pregnancy test;\n* Plan to move before the end of the trial or leave the local area for a long time during the scheduled trial visit;\n* Abnormal blood routine, blood biochemistry, urine routine, electrocardiogram or heart disease related indicators before vaccination (except for minor abnormalities judged by doctors to have no clinical significance);\n* Researchers believe that any situation that may affect the evaluation of the experiment;\n* Active tuberculosis patients;\n* For HIV infected individuals, the plasma HIV-1 RNA level during screening should be ≥ 200 copies\u002FmL, or positive test for hepatitis B, hepatitis C and syphilis;\n* For healthy people and men and women who have sex with each other, hepatitis B, hepatitis C, syphilis and HIV) are positive;\n* Individuals who experience severe allergic reactions after the first dose of vaccination;\n* Serious adverse events that are definitely related to the first dose of vaccination;\n* For those who are newly discovered or occur after the first dose of vaccination and do not meet the inclusion criteria or the exclusion criteria for the first dose, the researcher shall determine whether to continue participating in the trial.",{"count":141,"type":19},120,[117],"This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.",[23],[25,146,147,148,23],"safety","vaccine","immunogenicity","2025-10-02",{"date":151,"type":32},"2025-10-03",{"date":153,"type":32},"2025-01-22",{"date":155,"type":19},"2026-05-30",{"name":157,"class":132},"Shanghai Institute Of Biological Products",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":49,"sex":15,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":115,"phases":169,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":5},"100496573","phase-4-smallpox-vaccine-for-mpox-post-exposure-prophylaxis-a-cluster-rct-100496573","NCT05745987","Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT","SMART (Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster Randomized Controlled Trial)","SMART","Inclusion Criteria:\n\n1. Household member of person with laboratory confirmed mpox\n2. Age ≥ 2 years\n3. Within 14 days of onset of illness in mpox index case\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Breastfeeding\n3. Past serious allergic reaction to study vaccine components\n4. Previous smallpox vaccination\n5. Current or planned use of another investigational drug at any point during study participation","2 Years",{"count":168,"type":19},3000,[170],"PHASE4","A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.",[23],[91],"2025-07-03",{"date":176,"type":32},"2025-07-06",{"date":178,"type":32},"2024-09-17",{"date":180,"type":19},"2026-12-01",{"name":182,"class":39},"McMaster University",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":77},"100584170","evaluation-of-long-term-immunogenicity-of-a-boost-dose-of-mva-bn-vaccine-100584170","NCT06885853","Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine","M-BOOST-FR","Inclusion Criteria:\n\n* Men aged over 18 years\n* Have received two doses of MVA-BN vaccine as an initial schedule\n* Eligible for a booster dose of MVA-BN (according to the HAS recommendation)\n* Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment\n* Covered by social security (excluding AME)\n\nExclusion Criteria:\n\n* History of mpox (virologically confirmed)\n* Be under guardianship or curatorship\n* Be subject to a judicial protection measure\n* Have a contraindication to vaccination against mpox",{"count":191,"type":19},90,"This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine",[23],[23,195,196],"MVA-BN booster vaccine","HIV pre-exposure prophylaxis","2025-05-14",{"date":199,"type":32},"2025-05-15",{"date":201,"type":32},"2025-05-07",{"date":203,"type":19},"2027-11",{"name":205,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":115,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":228,"locationsCount":230},"100528115","phase-4-european-trial-into-mpox-infection-100528115","NCT06156566","European Trial Into Mpox Infection","European Randomised Clinical Trial on mPOX Infection","EPOXI","Inclusion Criteria:\n\n* Polymerase Chain Reaction (PCR) \u002FNucleic Acid Amplification Test (NAAT) -confirmed mpox infection\n* The presence of active skin or mucosal lesion(s)\n* Signed Informed Consent Form\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Body weight \\\u003C40 kg\n* Pregnant and breastfeeding patients are not eligible for inclusion in this study.\n* Lack of mental capacity to provide informed consent\n* Trial participation is considered not in the best interest of patient\n* Known hypersensitivity to the active substance or to any of the excipients of the study drug.\n* Use of contraindicated treatment repaglinide. (Repaglinide, an oral treatment for diabetes mellitus, may be discontinued while taking study treatment with the agreement of the patient's general practitioner, who may start alternate diabetes treatment if considered necessary.)\n* Previous, current or planned use of another investigational drug (tecovirimat) at any point during study participation.\n* The patient's own doctor considers there to be a definite indication for the patient to receive tecovirimat or the local guidelines establish that tecovirimat treatment should be initiated\n* The patient's own doctor considers there to be a definite contraindication to the patient receiving tecovirimat.\n* The patient suffers from hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.",{"count":215,"type":19},150,[170],"The goal of this randomized controlled double-blind clinical trial is to test the drug tecovirimat in patients with mpox (previously known as monkeypox) disease.\n\nThe main questions it aims to answer are:\n\n* Is tecovirimat effective in treating mpox infection.\n* Is tecovirimat safe to treat patients with mpox infection.\n\nParticipants will receive either the drug tecovirimat orally, 600 mg twice per day, or a matching placebo. The outcome of the infection and the side effect experienced will be compared between the two groups.",[23],[220,91,221],"tecovirimat","TPOXX","2025-03-24",{"date":224,"type":32},"2025-03-28",{"date":226,"type":32},"2024-08-09",{"date":36,"type":19},{"name":229,"class":39},"Miquel Ekkelenkamp",12,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":238,"phases":4,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":245,"locationsCount":4},"100215367","tecovirimat-st-246-treatment-for-orthopox-virus-exposure-100215367","NCT02080767","Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure","Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses","Inclusion Criteria:\n\n* DoD-affiliated personnel (including US civilian employees, contractors and other US personnel and dependents, as well as allied military forces and local nationals) of any age, not breastfeeding\n* Has been exposed to or infected with orthopox viruses (ie, variola (smallpox), vaccinia, monkeypox, or cowpox) OR Has developed serious complications from vaccinia vaccination (eg, eczema vaccinatum, progressive vaccinia, generalized vaccinia that is severe or persistent, and select cases of inadvertent inoculation due to severe pain related to mucosal involvement, ocular involvement) resulting from vaccination, secondary transmission, or other exposure\n* Is available for clinical follow-up for duration of the treatment and follow-up period\n* Must be able to swallow capsules\n\nExclusion Criteria:\n\n* Has hypersensitivity to tecovirimat\n* Unable or unwilling to cooperate with the requirements of the treatment protocol\n* Breast-feeding patients. Note that breast-feeding females will be counseled that tecovirimat has not been studied in breast-feeding women and may opt to cease breast-feeding for the duration of the treatment and at least 30 days after the last dose of drug and thus be eligible for enrollment. Women who choose to continue breast-feeding will not be enrolled in this treatment protocol.","EXPANDED_ACCESS","The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.",[120,23],"AVAILABLE","2025-03-05",{"date":244,"type":32},"2025-03-06",{"name":246,"class":247},"U.S. Army Medical Research and Development Command","FED",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":255,"targetDuration":257,"studyType":20,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":40},"100499498","observational-prospective-cohort-study-of-mpox-infection-in-brazil-netpox-100499498","NCT05784038","Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)","Observational, Prospective, Cohort Study of Mpox Infection in Brazil - NETPOX Cohort","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years with confirmed MPOX infection.\n\n(laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization)\n\nExclusion Criteria:\n\n* Inability to provide informed consent;\n* Patient who, judging by the study team, does not have a condition for decentralized follow-up",{"count":256,"type":19},80,"10 Months","The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.",[23,260],"MPOX","2024-07-16",{"date":263,"type":32},"2024-07-17",{"date":261,"type":32},{"date":266,"type":19},"2026-12",{"name":268,"class":39},"Hospital Israelita Albert Einstein"]